SCHEMBL4223041

SCHEMBL4223041

CC(=O)Nc1cccc(-c2ccc(C(=O)O)c(Nc3ccc(F)cc3)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.60
CNR1 P21554 1/20 0.48
IDO1 P14902 1/20 0.47
TDO2 P48775 1/20 0.47
XDH P47989 1/20 0.46
SLC22A12 Q96S37 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46
NPC1 O15118 1/20 0.46
TSHR P16473 1/20 0.46
RAB9A P51151 1/20 0.46
NQO2 P16083 2/20 0.46
AHR P35869 1/20 0.46
GRIK1 P39086 1/20 0.46
HSD17B1 P14061 1/20 0.45
HSD17B2 P37059 1/20 0.45
GAA P10253 1/20 0.45
DHODH Q02127 1/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4224024 0.90 MPO (0.52) MPOIDO1TDO2XDHSLC22A12
SCHEMBL4223069 0.85 MPO (0.61) MPOSMN1; SMN2AKR1C3AKR1C2NPC1
SCHEMBL4217388 0.85 DCLRE1B (0.53) MPOXDHSLC22A12AKR1C3AKR1C2
SCHEMBL4215664 0.85 ACLY (0.52) XDHSLC22A12AKR1C3AKR1C2GRIK1
SCHEMBL4217011 0.85 MPO (0.46) MPOCNR1IDO1TDO2SMN1; SMN2
SCHEMBL4213884 0.84 MCL1 (0.56) XDHSLC22A12AKR1C3AKR1C2DHODH
SCHEMBL4226484 0.83 XDH (0.54) XDHSLC22A12AKR1C3AKR1C2GRIK1
SCHEMBL4222877 0.83 MPO (0.56) MPOIDO1TDO2SMN1; SMN2AKR1C3
SCHEMBL4223004 0.83 XDH (0.50) XDHSLC22A12AKR1C3AKR1C2GRIK1
SCHEMBL4215681 0.81 GRIK1 (0.54) CNR1XDHSLC22A12AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 MPO 192/4885CNR1 1989/4885IDO1 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.